FAGR Fagron SA

Fagron publishes agenda for 2025 annual shareholders meeting

Fagron publishes agenda for 2025 annual shareholders meeting

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2025 – 8 AM CET

Fagron publishes agenda for 2025 annual shareholders meeting

The Board of Directors of Fagron NV invites shareholders to attend Fagron’s annual general meeting of shareholders on Monday 12 May 2025.

Agenda

The agenda includes the discussion of the annual report, the approval of the annual financial statements and the dividend proposal of €0.35 for the financial year 2024, and the approval of the remuneration policy.

The full agenda and further details can be found in the meeting documents.

Meeting and meeting documents

Fagron’s annual general meeting of shareholders will be held at its statutory seat, Venecoweg 20A, 9810, Nazareth (Belgium) and by audio and video conference on Monday 12 May 2025 at 3PM CET.

The convocation, including the agenda, and other documents related to this general meeting of shareholders can be found on the .

Further information

Ignacio Artola

Global Investor Relations Leader

Tel.

About Fagron

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 30 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment



EN
11/04/2025

Underlying

FAGRFagron SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

Free Trial
FAGR FAGRON SA

Fagron NV: 1 director

Five Directors at Fagron NV bought/sold 189,367 shares at between 16.230EUR and 20.506EUR. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...

05/15/25 May 15, 2025 1 EN
 PRESS RELEASE
Free
FAGR FAGRON SA

Fagron shareholders approve all voting items AGM

Fagron shareholders approve all voting items AGM Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 May 2025 – 7PM CET Fagron shareholders approve all voting items AGM Fagron, the leading global player in pharmaceutical compounding, held its annual general shareholders meeting today, where all the voting items were approved. ResolutionsThe annual general meeting approved, amongst other things, Fagron’s annual financial statements and dividend proposal of €0.35 per share for the fiscal year 2024, the remuneration policy and the appointment of the statutory auditor fo...

May 12, 2025 1 EN
 PRESS RELEASE
Free
FAGR FAGRON SA

Aandeelhouders Fagron keuren alle agendapunten van de jaarvergadering ...

Aandeelhouders Fagron keuren alle agendapunten van de jaarvergadering goed Gereglementeerde informatieNazareth (België)/Rotterdam (Nederland), 12 mei 2025 – 19:00u CET Aandeelhouders Fagron keuren alle agendapunten van de jaarvergadering goed Fagron, de toonaangevende mondiale speler in farmaceutische bereidingen, hield vandaag haar jaarlijkse algemene vergadering van aandeelhouders, waarbij alle ingediende voorstellen werden goedgekeurd. BesluitenDe jaarvergadering heeft onder andere Fagron’s jaarrekening en het dividendvoorstel van €0,35 per aandeel over het boekjaar 2024, het remunera...

May 12, 2025 1 EN
Guy Sips ... (+7)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Lewi
EURN EURONAV NV
AGS AGEAS SA/NV
FAGR FAGRON SA
GREEN GREENYARD NV
SEQUA SEQUANA MEDICAL
04/14/25 April 14, 2025 1 EN
Thomas Vranken
  • Thomas Vranken
FAGR FAGRON SA

Fagron Capital Markets Day feedback

Yesterday, Fagron hosted a Capital Markets Day where it laid out its strategic priorities for 2030. We see the updated Compounding for Growth strategy as a natural extension of the successful current trajectory. Financial targets are set for HSD-LDD organic CER revenue growth, a 21.0% REBITDA margin by 2027 progressively increasing thereafter to 2030, =70% operating cash conversion, =50% FCF conversion and 3.5% maintenance capex. Management continues to expect solid organic growth across all reg...

04/11/25 April 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch